Psychiatry and Clinical Psychopharmacology

Choking phobia induced by Sjögren Syndrome: a case report

Psychiatry and Clinical Psychopharmacology 2014; 24: Supplement S171-S172
Read: 967 Published: 18 February 2021

Sjögren’s Syndrome (SS) is a chronic autoimmune disorder of the exocrine glands with associated lymphocytic infiltrates of the affected glands. Dryness of the mouth and eyes results from involvement of the salivary and lacrimal glands. It can present with psychiatric symptoms; most commonly compatible with depression and anxiety. This paper introduces choking phobia induced with SS case. The interesting part in this case is that the patient was admitted to the internal medicine a myriad of times and in these admissions, his psychiatric complaints, such as fear of choking, prevailed over others; yet, SS was not considered. The 65-year-old patient was admitted to outpatient psychiatry service with complaints such as, fear of choking, sleep disorder, anhedonia, introversion and loss of motivation. About one year earlier, anxiety, which he developed about choking to death while he was in taking solid foods, resulted in sleep disorder and weight loss of more than 30 kg. The anxiety used to last all day long with the symptoms of tachycardia, sweating, dyspnea and swallowing problems. The patient was admitted to the emergency room many times with these complaints; nonetheless, the doctors could not diagnose nor ease his anxiety. In addition, he was admitted to the internal medicine with gastrointestinal complaints such as xerostomia, stomachache, dyspepsia, meteorism and constipation. The examinations exposed antral gastritis and he was medicated with proton-pump inhibitors. In his psychiatric history, he has suffered from depressive and hypomanic episodes since he had been 22-year-old. At his last psychiatry appointment, he was medicated with aripiprazole 5 mg/day and buspirone 15 mg/day, notwithstanding, his complaints did not cease and he was hospitalized to our inpatient service for detailed examination. He was diagnosed as bipolar disorder II and panic disorder and had HAM-D score of 36. At first, venlafaxine 37.5 mg and olanzapine 5 mg were administered, and then doses were incrementally increased to 150 mg and 10 mg, respectively. His xerostomia and xeroftalmia complaints led authors to suspect from SS; therefore, he was consulted to rheumatology clinic. Both Schirmer test (< 5 mm in 5 min) and ANA titres were positive (at a dilution of 1:100), as well as anti Ro/SS-A antibody test. Anti La/SS-B titre, other SLE and RA markers, and tests of the complement system were negative. His salivary gland scintigraphy results revealed decrease in extraction and excretion functions in bilateral parotis and submandibular glands; hence, SS diagnosis was confirmed. Electroencephalogram and MRI showed no biological abnormality. All scans were clear of malignancy about his loss of weight. Examining patients with multiple somatic complaints and mental symptoms, psychiatrists should keep SS in mind and consult rheumatology to search for SS autoantibodies in the serum, after a careful physical examination to emphasize signs of dry mouth and eyes. The diagnosis of primary SS could bring about a better adapted prescription of corticosteroids or immunosuppressive agents, together with specific psychotropic drugs, can induce remarkable relief from the psychiatric disorder. In general, this consideration holds for all autoimmune diseases.

EISSN 2475-0581